LY-3537021

N/A

Report date: 2025/12/01 16:48:21
NME

Base Information

Drug NameLY-3537021
Drug Alias NameLY-3537021
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingDrug-Related Side Effects and Adverse ReactionsVomiting +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesVetter Development Services Austria GmbhEli Lilly And CompanyLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsChemotherapy-induced nausea and vomitingDrug-Related Side Effects and Adverse ReactionsVomiting +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A